SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

Summary

This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.

Timeline

Start

2025-10

Primary completion

2026-10

Completion

2030-10

Drugs

Indications